– USA, CA – Applied Molecular Transport Inc. (Nasdaq: AMTI), a clinical-stage biopharmaceutical company, today announced the appointment of John Smither to its Board of Directors.
John will also join the Audit Committee as its Chair.
“We are delighted to have John join AMT’s Board of Director. John is a recognized industry leader whose extensive financial and corporate strategy experience will be instrumental as we anticipate four significant Phase 2 top-line data readouts for oral AMT-101 this year, in addition to advancing our transformative pipeline of novel biological therapeuticss,” said CEO and co-founder, Dr. Tahir Mahmood.
The company also announced the appointment of the current Director, Graham Cooper as Executive Chair alongside current Director, Helen Kim as the Lead Independent Director.
Dr. Mahmood added, “I am also pleased that Graham will be assuming the role of Executive Chair and Helen will be assuming the role of Lead Independent Director. Both Graham and Helen have been invaluable AMT Board members and their tremendous breadth and depth of experience in our space will continue to be critical to the future growth of AMT. I look forward to working alongside Graham as we scale AMT.”
About John W. Smither
Mr. Smither most recently served as CFO of Arcutis Biotherapeutics, Inc. Before Arcutis, Mr. Smither was CFO for Sienna Biopharmaceuticals. Before joining Sienna Biopharmaceuticals, Mr. Smither was interim CFO for Kite Pharma during its integration with Gilead, and before that, was CFO at Unity Biotechnology. Earlier, he served as CFO of Kythera Biopharmaceuticals, Inc. until it was acquired by Allergan for $2.1 billion. Mr. Smither also served in various roles at Amgen, including VP of finance and administration for Amgen’s European Division, head of internal audit, and executive director of corporate accounting. Before joining Amgen, he served as an audit partner at Ernst & Young LLP, a public accounting firm. He also served on the Board of Directors and Audit Committee Chairman of Achaogen, Inc., and currently serves on the Board of Directors and Audit Committee Chair of eFFECTOR Therapeutics.
Mr. Smither commented, “I am delighted to join the AMT Board of Directors during such a significant year for the company. I look forward to contributing to AMT’s future success and working with the other Board members, as AMT continues to execute on the vision of delivering novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases.”
Mr. Smither holds a Bachelor of Science in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant (inactive) and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants, and Financial Executives International.
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelial barrier. Active transport is an efficient mechanism that uses the cell’s machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local intestinal tissue or enter the systemic circulation to precisely address the relevant pathophysiology of the disease.
AMT’s headquarters, internal GMP manufacturing, and lab facilities are located in South San Francisco, CA.
For more information: https://www.appliedmt.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.